Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIVOT-RCC: Vaccine + IO in Renal Cell Carcinoma
NCT03598816Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2020
- Primary completion
- Dec 2022
01
Overview
Phase 2, randomised, open-label trial in renal cell carcinoma (RCC) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Percentage of patients with adverse events of grade 3 or higher at 4 weeks. Planned start Aug 2020; status: withdrawn.
02
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03598816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03598816.